The Korean Journal of Pain

The Korean Pain Society (대한통증학회)
권호 표지
DOI QR코드

DOI QR Code

The Effect of Urinary Trypsin Inhibitor Against Neuropathic Pain in Rat Models

  • Jung, Ki Tae (Department of Anesthesiology and Pain Medicine, Chosun University School of Medicine) ;
  • Lee, Hyun Young (Department of Anesthesiology and Pain Medicine, Chosun University School of Medicine) ;
  • Yoon, Myung Ha (Medical School, Chonnam National University) ;
  • Lim, Kyung Joon (Department of Anesthesiology and Pain Medicine, Chosun University School of Medicine)
  • Received : 2013.09.12
  • Accepted : 2013.09.21
  • Published : 2013.10.01
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Nerve injury sometimes leads to chronic neuropathic pain associated with neuroinflammation in the nervous system. In the case of chronic neuropathic pain, the inflammatory and algesic mediators become predominant and result in pain hypersensitivity following nervous system damage. It is well known that urinary trypsin inhibitor (ulinastatin, UTI) has an anti-inflammatory activity. Recently, the neuroprotective action of UTI on the nervous system after ischemic injury has been reported. Thus, we evaluated the neuroprotective effect of ulinastatin in a rat model of neuropathic pain. Methods: Neuropathic pain was induced with L5 spinal nerve ligation (SNL) in male Sprague-Dawley rats weighing 100-120 g. The rats were divided into 3 groups, with n = 8 in each group. The rats in the control group (group 1) were administered normal saline and those in group 2 were administered UTI (50,000 U/kg) intravenously through the tail vein for 3 days from the day of SNL. Rats in group 3 were administered UTI (50,000 U/kg) intravenously from the $5^{th}$ day after SNL. The paw withdrawal threshold was measured using the von Frey test for 3 days starting from the $5^{th}$ day after SNL. Results: The paw withdrawal thresholds were significantly increased in the rats of group 2 compared to the other groups (P < 0.05). Conclusions: Ulinastatin, which was administered for 3 days after SNL, increased the paw withdrawal threshold and it could have a neuroprotective effect in the rat model of neuropathic pain.

Keywords

References

  1. Austin PJ, Moalem-Taylor G. The neuro-immune balance in neuropathic pain: involvement of inflammatory immune cells, immune-like glial cells and cytokines. J Neuroimmunol 2010; 229: 26-50. https://doi.org/10.1016/j.jneuroim.2010.08.013
  2. Uceyler N, Sommer C. Cytokine regulation in animal models of neuropathic pain and in human diseases. Neurosci Lett 2008; 437: 194-8. https://doi.org/10.1016/j.neulet.2008.03.050
  3. Thacker MA, Clark AK, Marchand F, McMahon SB. Pathophysiology of peripheral neuropathic pain: immune cells and molecules. Anesth Analg 2007; 105: 838-47. https://doi.org/10.1213/01.ane.0000275190.42912.37
  4. Park KH, Lee KH, Kim H, Hwang SO. The anti-inflammatory effects of ulinastatin in trauma patients with hemorrhagic shock. J Korean Med Sci 2010; 25: 128-34. https://doi.org/10.3346/jkms.2010.25.1.128
  5. Aosasa S, Ono S, Mochizuki H, Tsujimoto H, Ueno C, Matsumoto A. Mechanism of the inhibitory effect of protease inhibitor on tumor necrosis factor alpha production of monocytes. Shock 2001; 15: 101-5. https://doi.org/10.1097/00024382-200115020-00004
  6. Park JH, Kwak SH, Jeong CW, Bae HB, Kim SJ. Effect of ulinastatin on cytokine reaction during gastrectomy. Korean J Anesthesiol 2010; 58: 334-7. https://doi.org/10.4097/kjae.2010.58.4.334
  7. Cao LJ, Wang J, Hao PP, Sun CL, Chen YG. Effects of ulinastatin, a urinary trypsin inhibitor, on synaptic plasticity and spatial memory in a rat model of cerebral ischemia/ reperfusion injury. Chin J Physiol 2011; 54: 435-42.
  8. Shu Y, Yang Y, Qiu W, Lu Z, Li Y, Bao J, et al. Neuroprotection by ulinastatin in experimental autoimmune encephalomyelitis. Neurochem Res 2011; 36: 1969-77. https://doi.org/10.1007/s11064-011-0520-4
  9. Kim SH, Chung JM. An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain 1992; 50: 355-63. https://doi.org/10.1016/0304-3959(92)90041-9
  10. Chung JM, Kim HK, Chung K. Segmental spinal nerve ligation model of neuropathic pain. Methods Mol Med 2004; 99: 35-45.
  11. Dogrul A, Ossipov MH, Lai J, Malan TP Jr, Porreca F. Peripheral and spinal antihyperalgesic activity of SIB-1757, a metabotropic glutamate receptor (mGLUR(5)) antagonist, in experimental neuropathic pain in rats. Neurosci Lett 2000; 292: 115-8. https://doi.org/10.1016/S0304-3940(00)01458-0
  12. Wang X, Xue Q, Yan F, Li L, Liu J, Li S, et al. Ulinastatin as a neuroprotective and anti-inflammatory agent in infant piglets model undergoing surgery on hypothermic low-flow cardiopulmonary bypass. Paediatr Anaesth 2013; 23: 209-16. https://doi.org/10.1111/pan.12073
  13. Zhu WJ, Yamanaka H, Obata K, Dai Y, Kobayashi K, Kozai T, et al. Expression of mRNA for four subtypes of the proteinase-activated receptor in rat dorsal root ganglia. Brain Res 2005; 1041: 205-11. https://doi.org/10.1016/j.brainres.2005.02.018
  14. Lee HL, Lee KM, Son SJ, Hwang SH, Cho HJ. Temporal expression of cytokines and their receptors mRNAs in a neuropathic pain model. Neuroreport 2004; 15: 2807-11.

Cited by

  1. Olanzapine Attenuates Mechanical Allodynia in a Rat Model of Partial Sciatic Nerve Ligation vol.28, pp.3, 2015, https://doi.org/10.3344/kjp.2015.28.3.185
  2. Autophagy: Can It be a New Experimental Research Method of Neuropathic Pain? vol.28, pp.4, 2015, https://doi.org/10.3344/kjp.2015.28.4.229
  3. Ulinastatin attenuates neuropathic pain induced by L5-VRT via the calcineurin/IL-10 pathway vol.12, pp.1744-8069, 2016, https://doi.org/10.1177/1744806916646785
  4. Gabexate mesilate ameliorates the neuropathic pain in a rat model by inhibition of proinflammatory cytokines and nitric oxide pathway via suppression of nuclear factor-κB vol.33, pp.1, 2013, https://doi.org/10.3344/kjp.2020.33.1.30
  5. Ulinastatin alleviates traumatic brain injury by reducing endothelin-1 vol.12, pp.1, 2013, https://doi.org/10.1515/tnsci-2021-0001